



(11) **EP 2 301 570 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 22

(51) Int Cl.:
A61K 51/10 ^(2006.01) **C07K 16/28** ^(2006.01)

(48) Corrigendum issued on:
25.01.2017 Bulletin 2017/04

(45) Date of publication and mention
of the grant of the patent:
27.01.2016 Bulletin 2016/04

(21) Application number: **10012296.9**

(22) Date of filing: **31.12.2003**

(54) **Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated and conjugated antibodies, antibody combinations and fusion protein**

Immunotherapie von B-zell Tumoren und Autoimmunerkrankungen unter Verwendung von unkonjugierten und konjugierten Antikörpern sowie Antikörperkombinationen und Fusionsproteinen

Immunothérapie s'appliquant aux tumeurs malignes des lymphocytes B et maladies auto-immunes utilisant des anticorps non conjugués et des anticorps conjugués, des combinaisons d'anticorps et des protéines de fusion

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**

(30) Priority: **31.12.2002 US 437145 P**

(43) Date of publication of application:
30.03.2011 Bulletin 2011/13

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
03786167.1 / 1 578 440

(73) Proprietor: **Immunomedics, Inc.**
Morris Plains, NJ 07950 (US)

(72) Inventors:
• **Goldenberg, David M.**
Morris Plains
New Jersey 07950 (US)
• **Hansen, Hans**
Morris Plains
New Jersey 07950 (US)

(74) Representative: **Bohmann, Armin K.**
Bohmann
Anwaltssozietät
Nymphenburger Straße 1
80335 München (DE)

(56) References cited:
WO-A-00/67796 WO-A-00/74718
WO-A-01/97855 WO-A-01/97858
WO-A-98/42378 WO-A1-00/67795

- **PRESS O W: "PROSPECTS FOR THE MANAGEMENT OF NON-HODGKIN'S LYMPHOMAS WITH MONOCLONAL ANTIBODIES AND IMMUNOCONJUGATES", CANCER JOURNAL FROM SCIENTIFIC AMERICAN, SCIENTIFIC AMERICAN, INC., NEW YORK, NY, US, vol. 4, no. SUPPL 2, July 1998 (1998-07), pages S19-S26, XP000929567, ISSN: 1081-4442**
- **SHIH L ET AL: "Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII JUL 2000 LNKD- PUBMED:10941903, vol. 49, no. 4-5, July 2000 (2000-07), pages 208-216, XP002619710, ISSN: 0340-7004**

EP 2 301 570 B8

- GRIFFITHS G L ET AL: "Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 11 JUN 1999 LNKD- PUBMED:10362149, vol. 81, no. 6, 11 June 1999 (1999-06-11), pages 985-992, XP002619711, ISSN: 0020-7136
- GOVINDAN S V ET AL: "Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters.", JOURNAL OF NUCLEAR MEDICINE : OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE DEC 2000 LNKD- PUBMED:11138697, vol. 41, no. 12, December 2000 (2000-12), pages 2089-2097, XP002619712, ISSN: 0161-5505
- OCHAKOVSKAYA R ET AL: "Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH JUN 2001 LNKD- PUBMED:11410483, vol. 7, no. 6, June 2001 (2001-06), pages 1505-1510, XP002619713, ISSN: 1078-0432
- PRESS O W ET AL: "Immunotherapy of Non-Hodgkin's lymphomas.", HEMATOLOGY / THE EDUCATION PROGRAM OF THE AMERICAN SOCIETY OF HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM. UNITED STATES 2001, 2001, pages 221-240, XP002276291, ISSN: 1520-4391
- TIETZE L F ET AL: "Carboranyl bisglycosides for the treatment of cancer by boron neutron capture therapy.", CHEMBIOCHEM: A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY. GERMANY 4 MAY 2001, vol. 2, no. 5, 4 May 2001 (2001-05-04), pages 326-334, XP002276289, ISSN: 1439-4227
- ILLIDGE T M ET AL: "RADIOIMMUNOTHERAPY OF CANCER: USING MONOCLONAL ANTIBODIES TO TARGET RADIOTHERAPY", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 6, no. 14, September 2000 (2000-09), pages 1399-1418, XP008020510, ISSN: 1381-6128
- ONG G L ET AL: "Single-cell cytotoxicity with radiolabeled antibodies.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH JAN 2001 LNKD- PUBMED:11205908, vol. 7, no. 1, January 2001 (2001-01), pages 192-201, XP002619714, ISSN: 1078-0432
- PRESTA L G: "ENGINEERING ANTIBODIES FOR THERAPY", CURRENT PHARMACEUTICAL BIOTECHNOLOGY, BENTHAM SCIENCE PUBLISHERS, BOCA RATON, FL, US, vol. 3, no. 3, 2002, pages 237-256, XP001105189, ISSN: 1389-2010
- REDDI ELENA: "Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumours", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B BIOLOGY, vol. 37, no. 3, 1997, pages 189-195, XP002276288, ISSN: 1011-1344
- DE VITA SALVATORE ET AL: "Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.", ARTHRITIS AND RHEUMATISM. UNITED STATES AUG 2002, vol. 46, no. 8, August 2002 (2002-08), pages 2029-2033, XP002276292, ISSN: 0004-3591
- STEIN R ET AL: "CD74: A new candidate target for the immunotherapy of B-cell neoplasms", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 18, 15 September 2007 (2007-09-15), pages 5556s-5563s, XP002510850, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1167
- L. Alinari ET AL: "Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma", Blood, vol. 117, no. 17, 28 April 2011 (2011-04-28), pages 4530-4541, XP055142749, ISSN: 0006-4971, DOI: 10.1182/blood-2010-08-303354
- GUPTA PANKAJ ET AL: "Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas", BLOOD, vol. 119, no. 16, April 2012 (2012-04), pages 3767-3778, ISSN: 0006-4971(print)
- Pankaj Gupta ET AL: "Abstract 4572: Heterodimerization of CD74 and CD20 by two hexavalent, bispecific, anti-CD20/CD74 antibodies leads to potent cytotoxicity in mantle cell lymphoma", Cancer research, vol. 71, no. 8 Supplement, 15 April 2011 (2011-04-15), pages 4572-4572, XP055193106, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2011-4572